Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine

Annals of Internal Medicine

Volumn 153, Issue 11, 2010, Pages 767-768

  Deenen, Maarten J ^a   Terpstra, Wim E ^b   Cats, Annemieke ^a   Boot, Henk ^a   Schellens, Jan H M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TEGAFUR; URACIL;

CANCER COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DNA POLYMORPHISM; DRUG ANTAGONISM; DRUG FEVER; DRUG INTOXICATION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; MUCOSA INFLAMMATION; NEUTROPENIA; PRESCRIPTION; PRIORITY JOURNAL; RECTUM CANCER;

EID: 79551717232     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-11-201012070-00023     Document Type: Letter

References (6)

1. NCI. Common Terminology Criteria for Adverse Events Version 3.0. Accessed at http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ ctcaev3.pdf on Accessed July 26, 2010
2. Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, et al. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res. 2006;12:549-55. [PMID: 16428499] (Pubitemid 43166148)
3. Ogura K, Nishiyama T, Takubo H, Kato A, Okuda H, Arakawa K, et al. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett. 1998;122:107-13. [PMID: 9464498] (Pubitemid 28058624)
4. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548-57. [PMID: 8862723] (Pubitemid 26276346)
5. Kim WY, Nakata B, Hirakawa K. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci. 2007;98:1604-8. [PMID: 17683513] (Pubitemid 47308458)
6. UFT Summary of Product Characteristics. Accessed at www.medicines.org.uk/ EMC/medicine/4399/SPC/Uftoral+Hard+Capsules on 26 July 2010.